ADVA
28.6.2022 09:02:07 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Tele2 Estonia has deployed the ADVA ALM fiber monitoring solution for real-time assurance across its national network. The compact, plug-and-play device boosts operational efficiency and service availability. This helps Tele2 Estonia to improve customer experience and offer enhanced SLAs. Managed by the Ensemble Controller network management system with Ensemble Fiber Director, the solution gives Tele2 Estonia’s field forces full control over their optical infrastructure. With its simple graphical overlay, the ADVA ALM precisely pinpoints the location of fiber impairments, enabling proactive maintenance, reducing repair times and preventing network outages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005471/en/
“With the ADVA ALM, we can offer even more value to our customers. Needing no calibration, it easily plugged into our infrastructure to instantly provide detailed info on any fiber event. Having the ability to rapidly respond to network issues and take immediate targeted action helps us ensure zero downtime and uninterrupted connectivity,” said Asse Hang, head of international sales at Tele2 Estonia. “This deployment is also central to our role as a sustainability leader. As the first communication service provider (CSP) in the Baltic region to have achieved climate neutral operations, we’re dedicated to reducing environmental impact in every aspect of our business. The ADVA ALM fiber monitoring solution enables us to dramatically decrease truck rolls, helping to further cut our carbon footprint”.
The ADVA ALM is a low-power, service-agnostic solution that offers total fiber infrastructure visibility. Requiring no active equipment at the user site, it’s now delivering comprehensive insight into the integrity and performance of Tele2 Estonia’s fiber infrastructure. The Ensemble Fiber Director provides a GIS-based, real-time graphical user interface that proactively notifies the CSP’s field forces of any fiber anomaly, enabling them to take countermeasures before problems develop and services are affected. With complete control, Tele2 Estonia is now significantly improving robustness and efficiency across its nationwide network, which is built on the ADVA FSP 3000.
“Tele2 Estonia is a CSP committed to adding value for its customers. Now it’s harnessing our ALM as part of its mission to eradicate network downtime. With round-the-clock fiber monitoring, Tele2 Estonia can initiate instant troubleshooting, helping to avoid service disruption and empowering it to offer more valuable SLAs,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Uniquely compact and affordable, there really is no other fiber assurance technology on the market that delivers as much with such little investment. Our ALM is the easiest way to guarantee superior network performance, save time and money, and help tackle environmental impact.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005471/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
